-
Mashup Score: 4PSMA-PET Implications for Extent and Survival Outcomes in High-Risk nmCRPC: An International Study - Boris Hadaschik - 4 month(s) ago
Alicia Morgans welcomes Boris Hadaschik to discuss the implications of using PSMA PET in non-metastatic castration-resistant prostate cancer treatment. Their focus lies on Dr. Hadaschik’s presentation examining the long-term outcomes and clinical implications of this technology. His study refers to a 2019 dataset involving 200 men diagnosed with high-risk non-metastatic CRPC. Dr. Hadaschik…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 1PSMA-PET Implications for Extent and Survival Outcomes in High-Risk nmCRPC: An International Study - Boris Hadaschik - 5 month(s) ago
Alicia Morgans welcomes Boris Hadaschik to discuss the implications of using PSMA PET in non-metastatic castration-resistant prostate cancer treatment. Their focus lies on Dr. Hadaschik’s presentation examining the long-term outcomes and clinical implications of this technology. His study refers to a 2019 dataset involving 200 men diagnosed with high-risk non-metastatic CRPC. Dr. Hadaschik…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0
A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0DEAR: Comparative Real-World Evidence on Darolutamide, Enzalutamide, and Apalutamide for Patients with nmCRPC in the United States - Neal D. Shore - 6 month(s) ago
Alicia Morgans engages with Neal Shore about the DEAR study, an analysis of real-world outcomes for non-metastatic castration-resistant prostate cancer (nmCRPC) patients treated with darolutamide, apalutamide, and enzalutamide. The study is made possible by an organization called PPS, which has access to electronic data. It includes information about when patients started their treatments,…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0PSMA-PET Implications for Extent and Survival Outcomes in High-Risk nmCRPC: An International Study - Boris Hadaschik - 7 month(s) ago
Alicia Morgans welcomes Boris Hadaschik to discuss the implications of using PSMA PET in non-metastatic castration-resistant prostate cancer treatment. Their focus lies on Dr. Hadaschik’s presentation examining the long-term outcomes and clinical implications of this technology. His study refers to a 2019 dataset involving 200 men diagnosed with high-risk non-metastatic CRPC. Dr. Hadaschik…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 5DEAR: Comparative Real-World Evidence on Darolutamide, Enzalutamide, and Apalutamide for Patients with nmCRPC in the United States - Neal D. Shore - 7 month(s) ago
Alicia Morgans engages with Neal Shore about the DEAR study, an analysis of real-world outcomes for non-metastatic castration-resistant prostate cancer (nmCRPC) patients treated with darolutamide, apalutamide, and enzalutamide. The study is made possible by an organization called PPS, which has access to electronic data. It includes information about when patients started their treatments,…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Time to Discontinuation on Darolutamide Longer in nmCRPC - 7 month(s) ago
Alicia K. Morgans, MD, MPH, discusses real-world evidence the shows patients with non-metastatic castration resistant prostate cancer on darolutamide have a longer time till discontinuation when compared with enzalutamide and apalutamide.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2PSMA-PET Implications for Extent and Survival Outcomes in High-Risk nmCRPC: An International Study - Boris Hadaschik - 8 month(s) ago
Alicia Morgans welcomes Boris Hadaschik to discuss the implications of using PSMA PET in non-metastatic castration-resistant prostate cancer treatment. Their focus lies on Dr. Hadaschik’s presentation examining the long-term outcomes and clinical implications of this technology. His study refers to a 2019 dataset involving 200 men diagnosed with high-risk non-metastatic CRPC. Dr. Hadaschik…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0DEAR: Comparative Real-World Evidence on Darolutamide, Enzalutamide, and Apalutamide for Patients with nmCRPC in the United States - Neal D. Shore - 9 month(s) ago
Alicia Morgans engages with Neal Shore about the DEAR study, an analysis of real-world outcomes for non-metastatic castration-resistant prostate cancer (nmCRPC) patients treated with darolutamide, apalutamide, and enzalutamide. The study is made possible by an organization called PPS, which has access to electronic data. It includes information about when patients started their treatments,…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 4
ASCO 2023 PATHOMIQ-PRAD, AI-enabled prognostic algorithm that predicts the risk of metastasis, radical prostatectomy specimens, non-metastatic castrate-resistant prostate cancer (nmCRPC).
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
PSMA-PET implications for extent and survival outcomes in high-risk #nmCRPC: an international study. @ProfHadaschik @unidue joins @CaPsurvivorship @DanaFarber for an insightfull discussion on UroToday > https://t.co/vtWfw0mtuj https://t.co/ex0WneOsoz